Multiple sclerosis: Elevated expression of matrix metalloproteinases in blood monocytes

Journal of Autoimmunity

Volumn 16, Issue 4, 2001, Pages 463-470

  Kouwenhoven, Mathilde ^a   Özenci, Volkan ^a   Gomes, Andreia ^a   Yarilin, Dmitry ^a   Giedraitis, Vilmantas ^a   Press, Rayomand ^a   Link, Hans ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

In situ hybridization; Matrix metalloproteinase; Monocytes; Multiple sclerosis

Indexed keywords

MATRIX METALLOPROTEINASE;

ARTICLE; BLOOD BRAIN BARRIER; CELL INFILTRATION; CLINICAL ARTICLE; DEMYELINATION; FEMALE; HUMAN; HUMAN CELL; MALE; MONOCYTE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 0034949509     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.2001.0505     Document Type: Article

References (54)

1. MS: A localized immune disease of the central nervous system
2. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications
3. Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity
4. Macrophages in multiple sclerosis
5. Staging of multiple sclerosis (MS) lesions: Pathology of the time frame of MS
6. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor
7. The matrix degrading metalloproteinases
8. The matrix metalloproteinases and their natural inhibitors: Prospects for treating degenerative tissue diseases
9. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions
10. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis
11. Extracellular matrix degradation by metalloproteinases and central nervous system diseases
12. Activation of human monocytes through CD40 induces matrix metalloproteinases
13. Neutral proteinases of human mononuclear phagocytes. Cellular differentiation markedly alters phenotype for serine proteinases, metalloproteinases, and tissue inhibitor of metalloproteinases
14. Comparative analysis of matrix metalloproteinases by immunocytochemistry, immunohistochemistry and zymography in human primary brain tumours
15. Biomechanical regulation of human monocyte/macrophage molecular function
16. Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-associated cells. A potential protective mechanism in plaque stability
17. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases
18. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions
19. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis
20. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study
21. Metalloproteinases and their tissue inhibitors in multiple sclerosis
22. Neutral metalloproteinases produced by mononuclear phagocytes: Enzyme profile, regulation, and expression during cellular development
23. TIMP-2 is required for efficient activation of pro-MMP-2 in vivo
24. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
25. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
26. Monocytes in multiple sclerosis: Phenotype and cytokine profile
27. Organ-specific autoantigens induce interferon-gamma and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis
28. The complete primary structure of human matrix metalloproteinase-3. Identity with stromelysin
29. Matrix metalloproteinases and diseases of the CNS
30. Extracellular matrix degradation by metalloproteinases and central nervous system diseases
31. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke
32. Interferon beta-1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9
33. Matrix metalloproteinase-9 release from monocytes increases as a function of differentiation: Implications for neuroinflammation and neurodegeneration
34. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis
35. Multiple sclerosis: Pro-and anti-inflammatory and metalloproteinases are affected differentially by treatment with IFN-β
36. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions
37. Matrilysin expression by human mononuclear phagocytes and its regulation by cytokines and hormones
38. Proteolytic and non-proteolytic activation of human neutrophil progelatinase B
39. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) is induced in rabbit articular chondrocytes by cotreatment with interleukin 1 beta and a protein kinase C activator
40. Interaction of 92-kDA type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the inhibitor of the proenzyme with stromyelisin
41. Expression of several matrix metalloproteinase genes in human monocytic cells
42. Expression of matrix metalloproteinase-9 and its inhibitors in mopnonuclear bloodcells of patients with multiple sclerosis
43. SV-40-transformed human lung fibroblasts secrete a 92 kDA type IV collagenase which is identical to that secreted by normal human macrophages
44. The interaction of purified rabit bone collagenase with purified rabit bone metalloproteinase inhibitor
45. The activity of tissue inhibitors of metalloproteinases is regulated by the C-terminal domain interactions: A kinetic analysis of the inhibition of gelatinase A
46. Characterization of a specific antiserum to rabbit stromelysin and demonstration of the synthesis of collagenase and stromelysin by stimulated rabbit articular chondrocytes
47. The purification of tissue inhibitor of metalloproteinases-2 from its 72 kDa progelatinase complex
48. Plasminogen activators and matrix metalloproteinases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system
49. Cloning and characterization of human tumor cell interstitial collagenase
50. Structure and expression of the human gene for the matrix metalloproteinase matrilysin
51. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages
52. cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment
53. Characterization of a human corneal metalloproteinase inhibitor (TIMP-1)